TY - JOUR
AU1 - Gorelik, Asher R.
AU2 - Williams, Leonard S.
AU3 - Steward, Jonathan T.
AB -  To the Editor: Metoclopramide is an antinauseant and gastrointestinal prokinetic agent commonly used to treat gastroparesis, nausea, and gastroesophageal reflux. Mechanisms of action include blockade of dopamine receptors centrally and peripherally and activation of serotonin receptors in the gut. Side effects are mild and transient, but extrapyramidal symptoms have been described. These are generally thought to be rare, although some reports suggest that they may be underestimated. The adverse effect that this medication may have upon functional capacity and rehabilitation may be easily overlooked. This study describes four patients who developed the syndrome of failure to thrive when treated with metoclopramide. Case 1: An 84‐year‐old man was started on metoclopramide 10 mg three times a day for gastric dysmotility. He later developed dysphagia with weight loss, depressive symptoms, cogwheel rigidity, bradykinesia, confusion, incontinence, and dependence in most activities of daily living (ADLs). A percutaneous endoscopic gastrostomy (PEG) tube was ultimately placed, but he continued to deteriorate and was ultimately placed on the inpatient hospice unit. When it was noted that he had no terminal diagnosis, he was transferred to the geriatric evaluation and management unit where metoclopramide was discontinued. His dysphagia, parkinsonian symptoms, and confusion improved rapidly, and 
TI - FAILURE TO THRIVE RELATED TO METOCLOPRAMIDE THERAPY
JF - Journal of American Geriatrics Society
DO - 10.1034/j.1600-0579.2003.00222.x
DA - 2003-05-01
UR - https://www.deepdyve.com/lp/wiley/failure-to-thrive-related-to-metoclopramide-therapy-cdkdxf3ldN
SP - 721
VL - 51
IS - 5
DP - DeepDyve
ER -